Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4066434 in KRAS Mutant Solid Tumors
NCT06607185Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1 trial of LY4066434 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-limiting Toxicities at 28 days and Treatment Emergent Adverse Events and Serious Adverse Events at 5 years. Started Oct 2024; status: active, not recruiting.
02
Drugs
LY4066434
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT06607185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607185.